Core One Labs (COOL.C) subsidiary, Vocan Biotechnologies, and the University of British Columbia (UBC), came to terms on a collaborative research agreement today, according to a press release.

The collaboration gives Vocan access to a well-funded, world-class research facility and team to enhance their position in the nascent psychedelic medicine space, especially given the increasing prevalence on research as psychedelic compounds advance into the mainstream medicine market.

“The collaboration with UBC Research Faculty enables Vocan to fast track its production method of biosynthesized psilocybin. The state-of-the-art equipment will allow for enhanced analysis of the compound, and the additional personnel exponentially increases the capacity of Vocan’s Research Team,” said Joel Shacker CEO of Core One Labs.

Psilocybin, MDMA and LSD have been the subject of research for the past few years, and shown significant therapeutic benefits for mental health conditions such as depression, anxiety, addiction and obsessive-compulsive disorder. Core One Labs, ostensibly a biotechnology research and technology life sciences enterprise, has been working on optimizing and maximizing the use of these molecules with their novel delivery system, a patent pending sublingual thin film oral strip.

The research will be conducted in the 10,000 square foot lab located in the Lower Mall Research Station at UBC. It sports a full research team, including a principal investigator, Post-Doctoral fellows, lab manager, research techs and research associates. Vocan’s specific research area will be in optimization of expression of enzymes, which will aid in the production of the prodrug psilocybin from the Psilocybe genus of mushrooms.

Vocan will provide the developed technology, and the UBC lab will use its skills to optimally express critical enzymes to enable recombinant synthesis in a suitable bacteria host.

Recombinant synthesis is the artificial creation of molecules by bringing together genetic material from multiple different sources to help make genetic sequences that wouldn’t normally be found in the genome. It’s how many designer drugs are made, and the use of biological factories using bacteria has been used to make everything from insulin to human growth hormone, and obviously needs to be configured for each individual product.

Artificial psilocybin is no different. The intent behind this is to increase the overall efficiency as well as the cost effectiveness of the process, and help Vocan’s scientists produce psilocybin using the fermentation.

Source: Stockwatch.com

COOL is up $0.07 today, and presently trading at $.99.

—Joseph Morton

Full disclosure: Core One Labs is an equity.guru marketing client.

Written By:

Joseph Morton

Joseph is a Vancouver-based author and journalist with both a communications degree and journalism diploma (and a few novels) under his belt. His joie de vivre is to spin difficult technical topics into more human-centric narratives. Buy him a coffee and he'll talk your ear off for hours about privacy issues, blockchain, cryptocurrency and martial arts. Don't talk to him if you're either a tomato, a bully, or if you're not a fan of either 1984 or Tender is the Night. No. You can still talk to him. Just be prepared to be told why you're wrong.

More By This Author
Tags:
Biotech
Featured Content
Psychedelics
Series
biotechnology
COOL.C
Core One Labs
Lower Mall Research Station
LSD
MDMA
Psilocybin
psychedelic aided therapy
psychedelic research
psychedelic therapies
psychedelics
UBC
University of British Columbia
Vocan
Vocan Biotechnologies
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments